Financial Performance - Q1 2025 - Total company net sales reached $30.5 million, a 38% increase year-over-year (YoY)[10] - Tru Niagen® net sales were $21.5 million, up 24% YoY[10] - Niagen® ingredient sales increased significantly to $8.0 million, a 95% YoY increase[10] - Gross margin improved to 63.4%, a 270 basis points increase YoY[10] - Net income was $5.1 million, or $0.07 earnings per share, an increase of $5.6 million and $0.08 YoY[10] - Adjusted EBITDA was $4.9 million, up $4.2 million YoY[10] - The company ended the quarter with $55.6 million in cash and no debt, with cash provided from operations at $7.9 million year-to-date[10] Sales Mix - Q1 2025 - E-commerce accounted for 58% of net sales in Q1 2025, compared to 55% in Q1 2024[26] - Watson's & Other B2B represented 20% of net sales in Q1 2025, up from 16% in Q1 2024[26] - Food-grade Niagen® contributed 19% of net sales in Q1 2025, down from 23% in Q1 2024[26] - Tru Niagen® net sales accounted for 71% of total net sales in Q1 2025, compared to 78% in Q1 2024[27] - Niagen®-related net sales remained at 97% of total net sales in both Q1 2025 and Q1 2024[27] Financial Outlook - 2025 - The company adjusted its full-year 2025 net sales growth outlook to between 20%-25%, previously approximately 18%[10] - Adjusted general and administrative expenses outlook was revised upwards by $7.0 to $8.0 million, previously $5.0 to $6.0 million[10]

Investor Presentation May 2025 Disclaimers Forward-Looking Information This presentation contains forward-looking statements. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. The words "may," "will," "should," "expects," "plans," "anticipates," "could," "intends," "targets," "projects," "contemplates," "believes," "estimates," "predicts," "potential" or "continue" and other expressions that are predictions of or indicate future events ...

Innovative Semiconductors / Photonics Design and Manufacturing Through AI Automation, Digital Twin Modeling, and Simulation Software APRIL 2024 From Atoms to Systems Q1 2025 Earnings Presentation May 7, 2025 Disclaimer This presentation is for informational purposes only and does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation to purchase any equity, debt or other financial instruments, of Silvaco Group, Inc. ("Silvaco" or the "Company"). The information contained her ...

investor.relations@arm.com https://investors.arm.com May 7, 2025 © 2025 Arm 1 Arm Holdings plc Q4 FYE25 Investor Presentation In addition to disclosing results determined in accordance with generally accepted accounting principles, or GAAP, Arm utilizes, and this presentation includes, certain non-GAAP financial measures that differ from measures calculated in accordance with GAAP. Arm's non-GAAP financial measures include non-GAAP cost of sales, non-GAAP gross profit (loss), non-GAAP gross margin, non-GAAP ...

Financial Performance (Q1 2025) - Total revenue reached $59.6 million, a 63% increase compared to $36.6 million in Q1 2024 [13, 28] - Software revenue grew to $48.8 million, a 46% increase from $33.4 million in Q1 2024 [13, 28] - Drug discovery revenue significantly increased to $10.7 million, a 237% increase compared to $3.2 million in Q1 2024 [13, 28] - Cash and marketable securities increased by 18% to $512.1 million as of March 31, 2025, compared to $435.7 million as of March 31, 2024 [28] - Deferred revenue, current and long term, increased by 265% to $210.0 million as of March 31, 2025, compared to $57.5 million as of March 31, 2024 [28] Financial Guidance (2025) - The company projects software revenue growth of 10% - 15% for the full year 2025 [13, 37] - Drug discovery revenue is expected to be between $45 million and $50 million for 2025 [13, 37] - Operating expense growth is anticipated to be less than 5% for 2025 [13, 37] - Software revenue for the second quarter of 2025 is projected to be in the range of $38 million to $42 million [13, 37] Proprietary Pipeline Milestones - Initial Phase 1 clinical data for SGR-1505 (MALT1) in R/R B-cell malignancies is expected in June 2025 [13, 40] - Initial Phase 1 clinical data for SGR-2921 (CDC7) in R/R AML/MDS is expected in the second half of 2025 [13, 40] - Initial Phase 1 clinical data for SGR-3515 (Wee1/Myt1) in solid tumors is expected in the second half of 2025 [13, 40]

Marqeta Earnings Supplement May 7, 2025 1 Safe Harbor Statement This earnings supplement contains "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this presentation include, but are not limited to, statements relating to Marqeta's quarterly and annual guidance; statements regarding Marqeta's business plans, business strategy and the continued success and growth of our cu ...

MAY 2025 Investor Presentation Forward-looking statements disclaimer This presentation contains forward-looking statements. We intend such forward-looking statements to be covered by the safe harbor provisions for forward- looking statements contained in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical facts contained in this presentation may be forward-looking statements. In some cases, you can identify forw ...

CSG Q1 2025 Earnings Presentation Brian Shepherd CEO & President Hai Tran CFO Safe Harbor Forward-Looking Statements + Disclaimers This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as "expect," "anticipate," "intend," "plan," "believe," "seek," "see," "will," "would," ...

Financial Performance - Total Q1 revenue reached $244.3 million, a 19% increase year-over-year[10, 44] - NUPLAZID sales in Q1 were $159.7 million, up 23% year-over-year, marking the highest ever quarterly sales[11, 23, 44] - DAYBUE sales in Q1 were $84.6 million, an 11% increase compared to Q1 2024[11, 17, 44] - Net income for Q1 was $19.0 million, a 14% increase year-over-year[44] - Earnings per share (EPS) for Q1 was $0.11, a 10% increase year-over-year[44] Product Updates - DAYBUE saw 954 unique patients receiving the therapy in Q1[18] - DAYBUE discontinuations decreased by 35% compared to Q4 2024 and 66% compared to Q1 2024[18] - 65% of active DAYBUE patients have been on therapy for 12 months or longer, with persistency rates above 50% at 12 months[18] Research and Development - Topline results from the COMPASS PWS Phase 3 trial with ACP-101 are now expected in early Q4 2025[12, 29] - The last patient-in for the COMPASS PWS Phase 3 trial is now expected in Q2 2025[29] - A Phase 2 study of ACP-204 in Lewy Body Dementia Psychosis (LBDP) is on track to initiate in Q3 2025[37] - Last patient-in for the Phase 2 study of ACP-204 in Alzheimer's Disease Psychosis (ADP) is expected in Q1 2026, with topline results expected mid-2026[38] Financial Guidance - The company anticipates total revenue between $1.03 billion and $1.095 billion for FY 2025[45] - NUPLAZID net sales are projected to be between $650 million and $690 million for FY 2025[45] - DAYBUE net sales are projected to be between $380 million and $405 million for FY 2025[45] - R&D expense is expected to be between $330 million and $350 million for FY 2025[45] - SG&A expense is expected to be between $535 million and $565 million for FY 2025[45]

1Q25 Earnings Presentation May 7, 2025 Published by: Sinclair, Inc. 111 NON-GAAP FINANCIAL MEASURES This presentation contains certain financial measures of Sinclair, Inc. (the "Company"), including Adjusted EBITDA, which are not prepared in accordance with U.S. generally accepted accounting principles ("GAAP") (collectively, the "non-GAAP financial measures"). Adjusted EBITDA is defined as earnings before interest, tax, depreciation and amortization, and non-recurring and unusual transaction, implementatio ...